Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 17

Results For "Non"

1703 News Found

Experts calls for urgent preventive action as hypertension cases rise
Healthcare | May 18, 2026

Experts calls for urgent preventive action as hypertension cases rise

Union Minister Prataprao Jadhav terms hypertension a “silent killer”; experts push for early screening, lifestyle correction and wellness-focused healthcare


Alembic Pharma receives USFDA tentative approval for Darolutamide tablets
Drug Approval | May 15, 2026

Alembic Pharma receives USFDA tentative approval for Darolutamide tablets

Darolutamide Tablets, 300 mg, had an estimated market size of US$ 3,155 million in the United States


Lilly and UNICEF launch $50M push to reach 30 million children with life-saving health care
News | May 15, 2026

Lilly and UNICEF launch $50M push to reach 30 million children with life-saving health care

The target reach is of more than 30 million young people and caregivers across 21 countries


Merck to showcase 100+ oncology studies at 2026 ASCO meeting
R&D | May 14, 2026

Merck to showcase 100+ oncology studies at 2026 ASCO meeting

Highlighting KEYTRUDA & expanding cancer pipeline


Suven Life Sciences reaches 76% milestone in Phase 3 masupirdine trial for Alzheimer’s agitation
Clinical Trials | May 14, 2026

Suven Life Sciences reaches 76% milestone in Phase 3 masupirdine trial for Alzheimer’s agitation

The accrued data from the Phase 3 study suggest that the baseline characteristics of the enrolled patients are consistent with those observed in previous studies


AI will eliminate 70-80% of current pharma commercial processes: Dushyant Sapre, Founder and CEO, SwishX
interviews | May 13, 2026

AI will eliminate 70-80% of current pharma commercial processes: Dushyant Sapre, Founder and CEO, SwishX

We are building an AI-native operating system for pharma sales and distribution


Vyome secures exclusive license from Impetis for selective JAK inhibitor programs
News | May 13, 2026

Vyome secures exclusive license from Impetis for selective JAK inhibitor programs

The global JAK inhibitors market is projected to REACH $56.78 billion by 2030, reflecting strong demand for targeted immunology treatments